Johnson & Johnson single-shot COVID-19 vaccine granted Emergency Use Listing by the WHO
On Mar. 12, 2021, Johnson & Johnson announced that the World Health Organization (WHO) had issued Emergency Use…
Abbott announced Pandemic Defense Coalition to help prevent future pandemics
On Mar. 11, 2021, Abbott announced the formation of the Abbott Pandemic Defense Coalition, a first-of-its-kind global scientific…
Rigel announced completion of patient enrollment for phase 2 trial of fostamatinib in hospitalized COVID-19 patients
On Mar. 11, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
ImmunityBio announced novel ACE2 decoy COVID-19 therapeutic that showed high binding to SARS-CoV-2 variants
On Mar. 11, 2021, ImmunityBio announced it was developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize…
Johnson & Johnson announced single-shot COVID-19 vaccine candidate received positive CHMP opinion
On Mar. 11, 2021, Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP)…
Real-world evidence confirmed high effectiveness of Pfizer-BioNTech COVID-19 vaccine
On Mar. 11, 2021, the Israel Ministry of Health (MOH), Pfizer and BioNTech announced real-world evidence demonstrating dramatically…
The FDA granted Department of Veterans Affairs first ever compassionate use for 3D-printed hearing device
On Mar. 11, 2021, the Department of Veterans Affairs (VA) announced that it had received compassionate use approval…
TGen launched COVID-19 study with Arizona dog and cat owners
On Mar. 10, 2021, TGen, an affiliate of City of Hope, announced the start of a scientific study…
CEPI and VBI Vaccines collaborated to advance vaccine candidates against COVID-19 variants
On Mar. 10, 2021, CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines announced a partnership to…
Thermo Fisher Scientific announced $600 million in capital investments to expand its bioprocessing production
On Mar. 10, 2021, Thermo Fisher Scientific announced more than $600 million in capital investments to expand its…
NIH scientists used human cerebral organoid to test drug for deadly brain disease
On Mar. 9, 2021, the NIH announced that approximately two years after establishing a human cerebral organoid system…
Agilent completed CE-IVD registration of qRT-PCR In vitro diagnostic kit for SARS-CoV-2 RNA detection
On Mar. 9, 2021, Agilent Technologies announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit…
NanoViricides pan-coronavirus COVID-19 drug candidates highly effective in pre-clinical animal atudies
On Mar. 9, 2021, NanoViricides announced that NV-CoV-2 and NV-CoV-2-R were found to be highly effective against a…
Oragenics announced Material Transfer Agreement with Biodextris for mucosal adjuvant for intranasal COVID-19 vaccine
On Mar. 9, 2021, Oragenics announced it had entered into a material transfer agreement with Biodextris for the…
VBI Vaccines announced enrollment in adaptive phase 1/2 study of prophylactic COVID-19 vaccine candidate
On Mar. 9, 2021, VBI Vaccines announced the initiation of enrollment of its Phase 1/2 clinical study of…
ImmunityBio and NantKwest began dosing participants in global trials for novel COVID-19 vaccine
On Mar. 8, 2021, ImmunityBio and NantKwest announced that the first cohorts of their South Africa and U.S….
AIM ImmunoTech announced first healthy subjects dosed in phase 1 intranasal Ampligen clinical study
On Mar. 8, 2021, AIM ImmunoTech announced that it had dosed the first healthy subjects in its Phase…
Abivax stopped phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy
On Mar. 5, 2021, Abivax announced tthat it was halting the miR-AGE phase 2b/3 clinical trial in high-risk…
Ridgeback Biotherapeutics and Merck announced preliminary findings from phase 2a trial of investigational COVID-19 therapeutic
On Mar. 5, 2021, Merck and Ridgeback Biotherapeutics, announced preliminary results from Ridgebackﾒs Phase 2a randomized, double-blind, placebo-controlled…
FDA issued authorization for first molecular non-prescription, at-home test
On Mar. 5, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the…
FDA authorized Cue Health’s COVID-19 test for at-mome and Over The Counter Use
On Mar. 5, 2021, Cue Health announced it had received Emergency Use Authorization (EUA) from the U.S. Food…
CureVac and Novartis signed initial agreement on manufacturing of COVID-19 vaccine candidate, CVnCoV
On Mar. 4, 2021, CureVac and Novartis announced an initial agreement for the manufacturing of CureVacﾒs COVID-19 vaccine…
NIH-sponsored ACTIV-3 clinical trial closed enrollment into two sub-studies
On Mar. 4, 2021, the NIH announced that the ACTIV-3 clinical trial evaluating the safety and efficacy of…
New evidence COVID-19 antibodies, vaccines less effective against variants
On Mar. 4, 2021, researchers at the University School of Medicine in St. Louis announced that three new,…
Soligenix announced positive progress in pre-clinical development of its COVID-19 vaccine
On Mar. 4, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVaxﾙ (heat stable COVID-19 vaccine program)…
Men, older adults and smokers more prone to infection by SARS-CoV-2
On Mar. 3, 2021, TGen, an affiliate of City of Hope announced that an in-depth analysis of the…
COVAX published first round of allocations
On Mar. 2, 2021, The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the WHO,…
NIH halted trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms
On Mar. 2, 2021, the NIH halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent…
NIH launched effort to understand MIS-C, range of SARS-CoV-2 effects on children
On Mar. 2, 2021, the NIH announced that it had launched a research effort to understand how SARS-CoV-2,…
CDC’s ACIP issued interim recommendation for use of Ebola vaccine
On Mar. 2, 2021, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with Merck’s Ervebo was…